Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Metrics to compare | LGVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLGVNPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −1.7x | −0.7x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price / Book | 1.2x | 1.5x | 2.6x | |
Price / LTM Sales | 16.3x | 7.1x | 3.2x | |
Upside (Analyst Target) | 363.4% | 163.2% | 44.5% | |
Fair Value Upside | Unlock | 23.0% | 6.6% | Unlock |